Board Meeting Outcome for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.

August 06, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Mumbai Samachar Marg, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Symbol: LUPIN Scrip Code: Equity - 500257 Subject: Outcome of the Board Meeting - Unaudited Financial Results for the quarter ended June 30, 2026 Dear Sir/Madam, Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. on Thursday, August 06, 2026, inter alia, unanimously approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. The said Unaudited Financial Results along with the Limited Review Reports of the Statutory Auditors thereon are enclosed herewith. The Board meeting commenced at 04.30 p.m. (IST) and concluded at 09.40 p.m. (IST). The above is for your information and dissemination. Thanking you, For LUPIN LIMITED AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754) Encl.: a/a LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 info@lupin.com | www.lupin.com LUPIN LIMITED Registared Office: 3rcl Floor, Kalpat:arulnspire, OlfWest:arn Express Highway, Santacruz (East), Mumbai 400 01111. Corporate Identity Number: L24100MH1983PLC029442 Tal: (91-22) 6640 2323 E-mail: lnfo@llupln.com Website: www.lupln.com LUPIN STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 (II' in million) Particulars Quarbtr Quarbtr Quarbtr Year Ended Ended Ended Ended 30/0612026 31/0312026 30/0612025 31/0312026 (Unaudited) (Audited) (Unaudiledl (Audited) (Refer note 4) 1) Revenue from operations a) Sales I income from operations 71,124.6 51,522.6 56,054.1 190,444.2 b) Other operating income 594.4 823.4 1,031.8 4,682.4 Totel Revenue from operwtlons 71,719.0 52,346.0 57,085.9 195,121..6 2) Other income 1,024.8 888.3 541.4 3,127.7 3) Totel income (1+2) 72,743.8 153,234.3 117,1127.3 198,2114.3 4) Expansea a) Cost of materials consumed 10,505.5 9,955.3 9,091.4 36,783.6 b) Purchases of stock-in-trade 3,089.0 2,745.8 3,119.3 11,923.2 c) Changes in inventories of finished goods. (99.6) (335.1) (397.5) 46.6 work-ill-progress and stock-in-trade [(increase)ldecrease] d) Employee benefrts expense 7,196.9 6,606.5 6,438.9 25,448.8 e) Finance cost 355.6 387.7 189.0 1,214.7 f) Depreciation, amortisation and impairment expense 1,900.1 1,no.5 1,767.3 7,071.8 g) Other expanses 13,619.9 13,667.5 12,021.9 49,159.8 h) Net loss I (gain) on foreign currency transactions 75.8 (3,110.1) (484.5) (6,271.0) Totel expenses 38,843.2 31,888.1 31,746.8 1215,377.15 5) Profit before exceptional Item and tax (3-4) 38,100.11 21,548.2 25,881.5 72,876.8 6) Exceptional items [income/(e xpense)] (Refer note 3) 4,4n.3 4,065.7 7) Profit before tax (5+8) 38,100.8 26,023.5 25,881.5 711,942.5 8) Tax expense Current tax (net) 8,925.7 4,711.2 4,515.4 13,512.9 Deferred tax (net) 28.9 (324.6) 85.4 (236.0) Total tax expense 8,954.6 4,366.6 4,600.8 13,276.9 9) Net Profit afbtr tax (NI) 27,146.0 21,838.9 21,280.7 83,886.6 10 ) Other Comprehensive Income I (Loss) (a) (i) Items that wil not be reclassified subsequently to (0.8) 46.4 (103.5) 61.8 profrt or loss (ii) Income tax relating to items that will not be reclassified 0.3 (16.2) 36.2 (21.6) subsequently to profit or loss (b) (i) Items that wil be reclassified subsequently to profit or 109.2 53.7 72.8 (324.3) loss (ii) Income tax relating to items that will be reclassified (38.1) (18.8) (25.4) 113.3 subsequently to profit or loss Other comprehensive income I (loss), net of tax 70.8 0.1 (19.8) (170.8) 11) ToteI comprehensive income, net of tax (9+1 0) 27,216.8 21,702.0 21,280.8 83,494.8 12) Paid up equity share capital (Face value it 21-each) 914.5 914.4 913.5 914.4 13) Other equity 300,423.3 14) Earnings per share (Face value off 21-each) (Not annualised for the quarters) (A) Before exceptional items a) Basic (in it) 59.37 37.01 46.60 129.18 b) Diluted (in f) 59.27 36.92 46.48 128.84 (B) After exceptional items a) Basic (in it) 59.37 47.35 46.60 139.38 b) Diluted (in it) 59.27 47.24 46.48 139.01 See accompanying notes to the standalone financial results. continued on Page 2 .. NOTES: 1. The above Standalone Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 06, 2026. The Statutory Auditors of the Company have carried out limited review of the above Standalone Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. 2. During the quarter ended June 30, 2026, 53,425 equity shares of ' 21-each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans {ESOP&), resulting in an increase in the paid-up equity share capital by ' 0. 1 million and securities premium account by ' 76.9 million. 3. Exceptional items a. The Company and its subsidiary are exposed to multiple civil lawsuits alleging anticompetitive behavior related to certain products and a possible violation of federal and stata antitrust laws. These lawsuits ware combined into the collection of similar cases referred to as In Re Generic Pharmaceuticals Antitrust Litigation. Such litigation are often resolved through settlement agreements. During the year ended March 31 2026, the Company on best estimate recorded a provision of' 4,493.9 million (USD 50.0 million) towards this litigation without admission of liability or wrongdoing. During the quarter ended March 31 , 2026, this provision has been recorded by the subsidiary and consequently reversed in the standalone results. In April 2026, the wholly owned subsidiary settled one of the ongoing dispute for an amount of' 2,654.1 million (USD 30.0 million) without admission of liability or wrongdoing. b. On February 09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with A&tellas towards ongoing dispute related to Mirebegron ER Tablets a generic version of Myrbatriq ER Tablets in US markets and agreed to pay USD 90.0 million. During the year ended March 31, 2026, the Company has compensated Lupin Pharmaceuticals, Inc., U.SA, for the settlement payment of' 1,364.7 million {USD 15.0 million) made by it and accordingly expensed. The balance amount of USD 75.0 million towards prepaid option has been paid and capitalised by the subsidiary. c. The Govemment of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 {collectively referred to as the "New Labour Codes'1, The New Labour Codes are effective from November 21, 2025 and introduce changes that indude, among other things, setting a uniform definition of wages. The Company has assessed the implications of the New Labour Codes and has recognized an incremental cost of ' 496.4 million during the year ended March 31, 2026. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards. d. During the year ended March 31, 2026, the Company has transferred its Over the Counter ('OTC1 and API R&D business in India to its wholly owned subsidiaries LupinlifB Consumer Healthcare Limited and Lupin Manufacturing Solutions Limited respectively, as a going concem on slump sale basis for a consideration of' 8,200.0 million and ' 180.0 million resulting in gain on divestment of' 6,589.6 million and ' 37.2 mi [Showing first 8,000 characters — download PDF for full document]